Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group
This 2004 Phase I clinical trial investigated the safety, pharmacokinetics, and preliminary efficacy of intravenous aviscumine (rViscumin), a recombinant mistletoe lectin, in 41 patients with advanced solid tumors refractory to standard therapies. Doses ranged from 10 to 6400 ng/kg, administered twice weekly. Dose-limiting toxicities included fatigue and reversible grade 3
June 26, 2025
No Comments